Heidelberg Engineering announced FDA clearance of the SPECTRALIS Flex Module, a multimodal diagnostic imaging platform designed for posterior segment imaging in pediatric and adult patients, particularly those in a supine position. This clearance expands access to advanced ophthalmic imaging for individuals who cannot be imaged using traditional tabletop OCT devices.
The SPECTRALIS Flex Module integrates the established SPECTRALIS technology onto a movable stand with an adjustable arm. This design allows for flexible positioning and imaging in various environments, addressing a critical need for patients with limited mobility. Ram Liebenthal, General Manager US at Heidelberg Engineering, stated, "Receiving FDA clearance for the SPECTRALIS Flex Module fulfills our vision of bringing Heidelberg image quality to all patients, regardless of their age or physical abilities."
The Flex Module supports multiple imaging modalities, including high-resolution OCT, OCT Angiography (OCTA), Fluorescein Angiography (FA), Indocyanine Green Angiography (ICG), Blue Laser Autofluorescence, MultiColor, and Widefield and Ultra-Widefield imaging. This comprehensive approach ensures thorough examinations for diverse patient populations.
Lejla Vajzovic, MD, FASRS, the principal investigator of the clinical trial, emphasized the module's utility: "The Flex Module has been an indispensable diagnostic tool for patients who would otherwise be difficult to image. Its exceptional image quality allows me to capture the fine details essential for precise diagnosis and treatment planning. For patients in a supine position, the ability to detect macular and optic nerve pathologies ensures that these vulnerable individuals receive timely, sight-saving treatments."
Heidelberg Engineering will showcase the SPECTRALIS Flex Module at the American Academy of Ophthalmology Congress in Chicago, October 19-21, 2024.
